FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2076723564> ?p ?o ?g. }

• W2076723564 endingPage "462" @default.
• W2076723564 startingPage "458" @default.
• W2076723564 abstract "To evaluate the toxicity and efficacy of combination chemotherapy with paclitaxel, cisplatin and 24 h continuous infusion of 5-FU/folinic acid in patients (pts) with unresectable, locally advanced or metastatic gastric adenocarcinoma. Forty-five chemotherapy-naive pts (28 male and 17 female) with a median age of 60 years (range 35–74) were enrolled. 5-FU 2 g/m2was given weekly over 24 h i.v. preceded by folinic acid 500 mg/m2as a 2 h infusion. Paclitaxel 175 mg/m2was administered as a 3 h-infusion on days 1 and 22 and cisplatin 50 mg/m2as 1 h infusion on days 8 and 29. Six weeks of therapy (days 1, 8, 15, 22, 29, 36) followed by 2 weeks rest were considered one cycle. A median of 3 cycles (range 1–4) were administered to 45 pts assessable for response, survival and toxicity. Five pts (11%) obtained a CR and 18 pts (40%) a PR (ORR 51%; 95% Cl: 35.8–66.3%). Responses were achieved in the liver, lymph nodes, lungs and at the site of the primary tumour. Nine pts (20%) had stable disease. Thirteen pts (29%) were considered to have failed treatment, 8 pts (18%) due to progressive disease and 5 pts (11%) who did not receive one complete cycle of therapy due to acute non-haematologic toxicity. The median progression-free and overall survival times were 9 months (range 1–36+) and 14 months (range 2–36+), respectively. Neutropenia WHO III°/IV° occurred in 7 pts (15%) with only 1 pt having grade IV. Additional non-haematologic WHO III°/IV° toxicities included nausea/vomiting in 5 (11%), alopecia in 22 (49%), and diarrhoea in 1 patient each (2%). Dose reductions or treatment delays were necessary in 8 pts (17%), mainly due to neutropenia. All pts were treated on an outpatient basis. The combination of paclitaxel, cisplatin and continuously infused 5-FU/folinic acid appears to be a highly active regimen for the treatment of pts with advanced gastric cancer. While the overall acceptable toxicity allows its use in the palliative setting, it may also be an attractive option to be tested for neoadjuvant or adjuvant treatment. © 2000 Cancer Research Campaign" @default.
• W2076723564 created "2016-06-24" @default.
• W2076723564 creator A5014692517 @default.
• W2076723564 creator A5019126848 @default.
• W2076723564 creator A5026559296 @default.
• W2076723564 creator A5044553314 @default.
• W2076723564 creator A5049792647 @default.
• W2076723564 creator A5064487920 @default.
• W2076723564 creator A5066624700 @default.
• W2076723564 creator A5078383767 @default.
• W2076723564 creator A5078597352 @default.
• W2076723564 creator A5086111821 @default.
• W2076723564 creator A5087150696 @default.
• W2076723564 date "2000-08-01" @default.
• W2076723564 modified "2023-10-10" @default.
• W2076723564 title "A phase II study of paclitaxel, weekly, 24-hour continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer" @default.
• W2076723564 cites W1843791750 @default.
• W2076723564 cites W1883602322 @default.
• W2076723564 cites W1937087099 @default.
• W2076723564 cites W1981480220 @default.
• W2076723564 cites W1982559524 @default.
• W2076723564 cites W1992408996 @default.
• W2076723564 cites W2000435707 @default.
• W2076723564 cites W2001281232 @default.
• W2076723564 cites W2017565612 @default.
• W2076723564 cites W2030822423 @default.
• W2076723564 cites W2033166317 @default.
• W2076723564 cites W2034288807 @default.
• W2076723564 cites W2036409540 @default.
• W2076723564 cites W2037605675 @default.
• W2076723564 cites W2041173222 @default.
• W2076723564 cites W2045568790 @default.
• W2076723564 cites W2059396892 @default.
• W2076723564 cites W2062636381 @default.
• W2076723564 cites W2065895095 @default.
• W2076723564 cites W2069434099 @default.
• W2076723564 cites W2129762276 @default.
• W2076723564 cites W2130522735 @default.
• W2076723564 cites W2167805334 @default.
• W2076723564 cites W2223406810 @default.
• W2076723564 cites W2258360017 @default.
• W2076723564 cites W2269468903 @default.
• W2076723564 cites W2416450954 @default.
• W2076723564 cites W2419071787 @default.
• W2076723564 cites W2419194755 @default.
• W2076723564 cites W2442430918 @default.
• W2076723564 cites W78979634 @default.
• W2076723564 cites W88184138 @default.
• W2076723564 doi "https://doi.org/10.1054/bjoc.2000.1295" @default.
• W2076723564 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2374647" @default.
• W2076723564 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10945491" @default.
• W2076723564 hasPublicationYear "2000" @default.
• W2076723564 type Work @default.
• W2076723564 sameAs 2076723564 @default.
• W2076723564 citedByCount "111" @default.
• W2076723564 countsByYear W20767235642012 @default.
• W2076723564 countsByYear W20767235642013 @default.
• W2076723564 countsByYear W20767235642014 @default.
• W2076723564 countsByYear W20767235642019 @default.
• W2076723564 countsByYear W20767235642021 @default.
• W2076723564 countsByYear W20767235642022 @default.
• W2076723564 crossrefType "journal-article" @default.
• W2076723564 hasAuthorship W2076723564A5014692517 @default.
• W2076723564 hasAuthorship W2076723564A5019126848 @default.
• W2076723564 hasAuthorship W2076723564A5026559296 @default.
• W2076723564 hasAuthorship W2076723564A5044553314 @default.
• W2076723564 hasAuthorship W2076723564A5049792647 @default.
• W2076723564 hasAuthorship W2076723564A5064487920 @default.
• W2076723564 hasAuthorship W2076723564A5066624700 @default.
• W2076723564 hasAuthorship W2076723564A5078383767 @default.
• W2076723564 hasAuthorship W2076723564A5078597352 @default.
• W2076723564 hasAuthorship W2076723564A5086111821 @default.
• W2076723564 hasAuthorship W2076723564A5087150696 @default.
• W2076723564 hasBestOaLocation W20767235641 @default.
• W2076723564 hasConcept C121608353 @default.
• W2076723564 hasConcept C126322002 @default.
• W2076723564 hasConcept C141071460 @default.
• W2076723564 hasConcept C2776694085 @default.
• W2076723564 hasConcept C2777063308 @default.
• W2076723564 hasConcept C2777292972 @default.
• W2076723564 hasConcept C2778239845 @default.
• W2076723564 hasConcept C2779804826 @default.
• W2076723564 hasConcept C2780456651 @default.
• W2076723564 hasConcept C29730261 @default.
• W2076723564 hasConcept C71924100 @default.
• W2076723564 hasConcept C90924648 @default.
• W2076723564 hasConceptScore W2076723564C121608353 @default.
• W2076723564 hasConceptScore W2076723564C126322002 @default.
• W2076723564 hasConceptScore W2076723564C141071460 @default.
• W2076723564 hasConceptScore W2076723564C2776694085 @default.
• W2076723564 hasConceptScore W2076723564C2777063308 @default.
• W2076723564 hasConceptScore W2076723564C2777292972 @default.
• W2076723564 hasConceptScore W2076723564C2778239845 @default.
• W2076723564 hasConceptScore W2076723564C2779804826 @default.
• W2076723564 hasConceptScore W2076723564C2780456651 @default.
• W2076723564 hasConceptScore W2076723564C29730261 @default.
• W2076723564 hasConceptScore W2076723564C71924100 @default.
• W2076723564 hasConceptScore W2076723564C90924648 @default.

• next